tailored Guizhi decoction
PreclinicalSmall molecule
tailored Guizhi decoction is one of 8 small molecule programs targeting Anosmia. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
7
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
14 competitors in Anosmia
#DrugCompanyPhaseTrials
1Theo-Dur
PfizerApproved
Acetadote
AArbor Pharmaceuticals, Inc.
Approved
Stromectol
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Cerebrolysin
EEver Neuro Pharma GmbH
Approved
Pulmicort
SSalix
Phase 2
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 1
N-Acetyl Cyteien
SStanford University
Phase 1
tailored Guizhi decoction
TTaichung Veterans General Hospital
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for tailored Guizhi decoction. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details